News | SCAI | June 01, 2023

Ticogrelor Monotherapy Post PCI Associated with Similar Rates of Revascularization as Duel Antiplatelet Therapy

Analysis of TWILIGHT trial shines light on Effect of Therapies following percutaneous coronary intervention 

Analysis of TWILIGHT trial shines light on Effect of Therapies following percutaneous coronary intervention

Getty Images


June 1, 2023 — New insights from the TWILIGHT trial showed that ticagrelor monotherapy after three months of ticagrelor plus aspirin was associated with similar rates of recurrent coronary revascularization, major adverse cardiac and cerebrovascular events (MACCE) and a lower risk of net adverse clinical events (NACE) compared with duel antiplatelet therapy (DAPT). The results from the randomized control trial of more than 7,000 patients were presented as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions (SCAI) 2023 Scientific Sessions. 

Despite advances in percutaneous coronary intervention (PCI) techniques, devices and secondary prevention, repeat revascularization remains a concern and is associated with increased morbidity, hospitalization and healthcare costs. 

In the TWILIGHT trial, high-risk patients who were event-free and adherent to a ticagrelor-based DAPT for three months after PCI were randomized to ticagrelor plus aspirin or ticagrelor plus placebo for 12 additional months. The primary endpoint was repeat revascularization due to recurrent or persistent symptomatic myocardial ischemia. Secondary endpoints included target lesion revascularization (TLR), target vessel revascularization (TVR) and major adverse cardiac and cerebrovascular events (MACCE) and net adverse clinical events (NACE). All endpoints were adjudicated and assessed at 12 months after randomization in the per-protocol population. 

Among 7,039 patients, ticagrelor monotherapy and ticagrelor plus aspirin were associated with a similar risk of repeat revascularization (7.1% vs 6.6%, HR 1.09, 95% CI 0.90-1.30), TLR, TVR and MACCE, while NACE was lower with ticagrelor monotherapy.  The results also showed that clinically-driven revascularization was associated with an excess risk for subsequent death, myocardial infarction or stroke (aHR 2.92, 95% CI 1.82 – 4.67). 

“In high-risk PCI patients, it’s critical to lessen the occurrence of repeat revascularization,” said Usman Baber, M.D., Associate Professor of Medicine at the University of Oklahoma Health Sciences Center, and lead author of the study. “The findings presented today from the TWILIGHT trial provide a greater understanding of the impact of DAPT and ticagrelor monotherapy following PCI for the clinical community.” 

For more information: www.scai.org 

 

Find more SCAI23 conference coverage here 

 

Related TWILIGHT Trial Content: 

Long-term Dual Antiplatelet Therapy Benefits Reinforced in SCAI Late-breaking Study 

Shorter DAPT With Xience Stent is Noninferior to Standard DAPT 

TWILIGHT Trial Substudy Examines Bioabsorbable Polymer vs. Durable Polymer Drug-Eluting Stents in High-Risk PCI 

VIDEO: TWILIGHT Trial Shows Benefit to Ticagrelor Monotherapy After Stent Implantation 


Related Content

News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — People with a small aortic annulus, a part of the heart’s anatomy where the left ventricle meets the ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 8, 2024 — People with diabetes who had suffered a heart attack derived no clinical benefit from edetate disodium ...

Home April 08, 2024
Home
Subscribe Now